 BOSTON, Nov. 07, 2022 GLOBE NEWSWIRE -- Inozyme Pharma, Inc. Nasdaq: INZY, a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Axel Bolte, MSc, MBA, the companys co-founder, president, and chief executive officer, will participate in the following investor conferences: 